The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

Collaboration between giant pharmaceutical corporations and patients with very little power just doesn’t work, according to ...

Health tech startup Dandelion Health launched a clinical artificial intelligence marketplace that merges third-party ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going ...

However, after its phase 1 success with TERN-601, it will raise more money by taking advantage of its soaring stock price and ...

Edward Sheldon believes these three growth stocks are capable of generating spectacular returns for his portfolio over the ...

Founded in 2017, Hims & Hers originally specialized in selling over-the-counter medications and personal care products through its online platform as well as brick-and-mortar retailers such as Target.

A drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6 when combined with ...